samedan logo
 
 
spacer
home > pmps > spring 2003 > generic medicine - what's in it for the health service?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Generic Medicine - What's in it for the Health Service?

While pharma faces its toughest challenge yet from generics competition, Bluepharma's newly opened Research & Development Services Laboratories will boost the flow of new products through its pharma clients' commercial pipeline while the company continues to expand its contract manufacturing services business.

In March 2003 Bluepharma, a contract production services organisation based in Coimbra, Portugal, a spin-off from Bayer, launched its brand new laboratories offering product research and development services.

This event took place in the same week that Portugal's Government introduced a system of reimbursement by referential pricing (see Generic Medicine - What's in it for the Health Service, page 76), which will pose one of the toughest challenges ever for the nation's pharma industry entering the market for generic medicines.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Patricia Lobo, Editor of PMPS

Dr Luis Filipe Pereira, Minister for Health at Inauguration of Bluepharma's New R&D Laboratories

Dr Paulo Barradas, CEO of Bluepharma

Dr Isolina Mesquita, Director of Operations & Plant Manager

Professor Sergio Simoes, Head of Bluepharma's R&D Laboratory


spacer
Dr Patricia Lobo
spacer
spacer
spacer
Dr Luis Filipe Pereira
spacer
spacer
spacer
Dr Paulo Barradas
spacer
spacer
spacer
Dr Isolina Mesquita
spacer
spacer
spacer
Professor Sergio Simoes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Bio-Rad Introduces Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays to Quickly Measure Neutralizing Antibodies Against SARS-CoV-2 Virus

HERCULES, Calif.–December 20, 2021–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Bio-Plex™ Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays, for research use only (RUO).
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement